The “Global Atopic Dermatitis (AD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025” report has been added to Research and Markets’ offering.
The global atopic dermatitis (AD) treatment market was valued at US$ 4.04 Billion in 2016, and is expected to reach US$ 7.66 Billion by 2025, expanding at a CAGR of 7.4% from 2017 to 2025.
It is observed that currently anti-inflammatory agents is a major revenue generating segment as these drugs are preferably used as a first line therapy after failure of skin care and moisturizers due to its effectiveness. Strong pipeline molecules such as ABT-494, apremilast, LY-3009104, GSK-2894512, REGN-668, GBR-830, MEDI-9929, nemolizumab, OPA-15406, PF-04965842, secukinumab and tralokinumab are expected to show AD treatment market growth during forecast period 2017-2025.
In the base year 2016, North America dominated the global AD treatment market due to large number of target population, higher treatment awareness, swift adoption of novel medications, and better reimbursement policies. On the other hand, Asia Pacific will show highest AD treatment market growth during forecast period due to increasing healthcare awareness among general population and growing partnership of key players with local manufacturer.
The atopic dermatitis (AD) treatment market is observed to be highly competitive and comprises large number of players. However, some major market players are LEO Pharma A/S, AbbVie Inc., Encore Dermatology Inc., F. Hoffmann-La Roche AG, Glaxosmithkline plc., Medimmune (Astrazeneca), Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Valeant Pharmaceuticals Inc. and other.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Atopic Dermatitis (AD) Treatment Market Analysis
Chapter 4 Global Atopic Dermatitis (AD) Treatment Market, by Drug Type
Chapter 5 Global Atopic Dermatitis (AD) Treatment Market, By Geography
Chapter 6 Company Profiles
– AbbieVie Inc.
– Encore Dermatology Inc.
– F. Hoffmann-La Roche AG
– Glaxosmithkline plc.
– LEO Pharma A/S
– Medimmune LLC. (Astrazeneca)
– Novartis AG
– Pfizer Inc.
– Regeneron Pharmaceuticals Inc.
– Sanofi S.A.
– Valeant Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/research/nwghg3/global_atopic?w=3